CA
NZ
UK
AU
IND
US
…
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -7.23M | -6.99M | -4.91M | -7.61M | -4.95M |
| Net income | -7.23M | -6.99M | -4.91M | -9.11M | -3.53M |
| Selling general administrative | 4124832.00M | 3.61M | 3.25M | 4.47M | 1.83M |
| Selling and marketing expenses | 1900598.00M | 0.98M | 0.76M | 0.54M | 0.33M |
| Gross profit | -0.22M | -0.08M | -0.00M | -0.00M | -0.01M |
| Reconciled depreciation | 0.23M | 0.19M | 0.16M | 0.19M | 0.19M |
| Ebit | -7.05M | -6.46M | -4.30M | -6.10M | -2.95M |
| Ebitda | -6.82M | -6.26M | -4.14M | -5.90M | -4.66M |
| Depreciation and amortization | 0.23M | 0.19M | 0.16M | 0.20M | -1.70M |
| Operating income | -7.05M | -5.51M | -4.88M | -6.10M | -2.95M |
| Other operating expenses | 7.13M | 5.56M | 4.95M | 6.16M | 3.01M |
| Interest expense | 0.00M | 0.54M | 0.61M | 1.51M | 0.48M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.41M | 0.00M | 0.00M | 0.00M | - |
| Net interest income | 0.41M | -0.54M | -0.61M | -1.51M | -0.48M |
| Income tax expense | - | 0.00M | -0.00M | 1.51M | -1.42M |
| Total revenue | 0.08M | 0.05M | 0.08M | 0.06M | 0.06M |
| Total operating expenses | 6.83M | 5.43M | 4.88M | 6.09M | 2.94M |
| Cost of revenue | 0.30M | 0.13M | 0.08M | 0.07M | 0.07M |
| Total other income expense net | -0.18M | -1.48M | -0.04M | -1.51M | -2.00M |
| Net income from continuing ops | -7.23M | -6.99M | -4.91M | -7.61M | -4.95M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 13672404.00M | 2.12M | 2.46M | 3.21M | 1.89M |
| Intangible assets | 1251531.00M | 1.29M | 1.17M | 1.21M | 1.14M |
| Other current assets | 380914.97M | 0.35M | 0.14M | 0.20M | 0.27M |
| Total liab | 837287.00M | 1.15M | 3.19M | 1.42M | 7.62M |
| Total stockholder equity | 12835117.00M | 0.97M | -0.73M | 1.79M | -5.73M |
| Other current liab | 837286.67M | 0.62M | 1.30M | 0.96M | 4.56M |
| Common stock | 9.00M | - | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -58495940.00M | -51.26M | -44.28M | -39.91M | -31.89M |
| Other assets | - | - | 0.00M | 0.00M | - |
| Cash | 12015789.00M | 0.45M | 1.03M | 1.47M | 0.45M |
| Total current liabilities | 837287.00M | 1.15M | 3.19M | 1.42M | 7.62M |
| Net debt | -12015789.00M | -0.45M | 0.09M | -1.47M | 1.55M |
| Short term debt | - | - | 1.13M | - | 2.00M |
| Short long term debt | - | - | 1.13M | - | 2.00M |
| Short long term debt total | - | - | 1.13M | - | 2.00M |
| Other stockholder equity | 71331119.33M | 52.23M | 43.55M | 41.69M | 26.16M |
| Total current assets | 12396704.00M | 0.82M | 1.19M | 1.99M | 0.73M |
| Short term investments | - | 0.04M | - | - | - |
| Net receivables | 0.03M | 0.02M | 0.01M | 0.02M | 0.01M |
| Inventory | - | - | 0.00M | 0.30M | - |
| Accounts payable | 0.33M | 0.53M | 0.76M | 0.46M | 1.06M |
| Non currrent assets other | - | - | 0.10M | 0.00M | - |
| Non current assets total | 1275700.00M | 1.30M | 1.27M | 1.22M | 1.16M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.32M | -0.12M | -0.21M | -0.15M |
| Total cashflows from investing activities | -203902.00M | -0.32M | -0.12M | - | - |
| Net borrowings | 0.00M | -0.30M | 2.25M | - | - |
| Total cash from financing activities | 18945234.00M | 5.03M | 3.31M | 6.55M | 2.94M |
| Net income | -7233629.00M | -6.99M | -4.91M | -7.61M | -4.95M |
| Change in cash | 11577128.00M | -0.57M | -0.45M | 1.03M | 0.44M |
| Begin period cash flow | 463661.00M | 1.03M | 1.48M | 0.45M | 0.01M |
| End period cash flow | 12040789.00M | 0.46M | 1.03M | 1.48M | 0.45M |
| Total cash from operating activities | -7164204.00M | -5.27M | -3.65M | -5.31M | -2.35M |
| Issuance of capital stock | 20.26M | 6.57M | 1.46M | 8.55M | - |
| Depreciation | 227406.00M | 0.19M | 0.16M | 0.19M | 0.19M |
| Other cashflows from investing activities | -203901.80M | -0.32M | -0.12M | - | - |
| Dividends paid | 5425.00M | 0.06M | - | 0.42M | - |
| Change to account receivables | -0.01M | 0.01M | -0.00M | -0.01M | 0.02M |
| Sale purchase of stock | -1.21M | 0.00M | -0.00M | - | - |
| Other cashflows from financing activities | 18950640.05M | -0.25M | -0.40M | 0.42M | -0.15M |
| Capital expenditures | 0.02M | 0.32M | 0.12M | 0.21M | 0.15M |
| Change in working capital | -0.36M | -0.56M | 0.62M | 0.81M | 0.68M |
| Stock based compensation | 105368.00M | 0.29M | 0.46M | 1.29M | 0.18M |
| Other non cash items | -263348.64M | 1.80M | 0.02M | 0.00M | 1.90M |
| Free cash flow | -7164204.00M | -5.59M | -3.77M | -5.52M | -2.50M |
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| ACONW Aclarion Inc |
-0.00 4.26% |
0.02 | - | - | - | - |
| DOGEF Orsted A/S |
- -% |
19.33 | 28.82 | 0.66 | 6.50 | 0.07 |
| TBB AT&T Inc. 5.35% GLB NTS 66 |
0.04 0.23% |
17.64 | 4.60 | - | - | - |
| CCZ Comcast Holdings Corp |
1.95 3.12% |
64.50 | 55.07 | - | - | - |
| STMZF Scottish Mortgage Investment Trust PLC |
-0.31 1.50% |
20.69 | - | - | 2.56 | - |
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
| Name | Title | Year Born |
|---|---|---|
| Dr. Jeffrey John Thramann M.D. | Exec. Chairman | 1965 |
| Mr. Brent Ness | CEO, Pres & Director | 1967 |
| Mr. John Lorbiecki | Chief Financial Officer | 1964 |
| Mr. Ryan Bond | Chief Strategy Officer | 1975 |
| Dr. Jeffrey John Thramann M.D. | Executive Chairman | 1965 |
| Mr. Ryan Bond | Chief Strategy Officer | 1973 |
| Mr. Brent Ness | CEO, President & Director | 1967 |
| Mr. John Lorbiecki | Chief Financial Officer | 1963 |
| Mr. Ryan Bond | Chief Strategy Officer | 1972 |
| Dr. Jeffrey John Thramann M.D. | Executive Chairman | 1966 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.52%
Communication Services
+0.32%
Consumer Cyclical
+1.01%
Consumer Defensive
+0.00%
Energy
+0.01%
Financial Services
+0.62%
Financials
-2.62%
Healthcare
+0.51%
Industrials
+0.71%
Real Estate
+0.72%
Technology
-0.46%
Utilities
+0.54%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...